Preface

Abstract

This is the third ATTD Yearbook and by now we already know that the book makes its way to the hands of many clinicians, diabetes educators and researchers in academic institutes and to the members of the diabetes industry as well as many others interested in changing the life of people with diabetes all over the world. The availability of the book on the ATTD webpage and in PubMed facilitates access to anybody in the world interested in new technologies and therapies in diabetes. Also this year, the book consists of short summaries of selected papers published in peer-reviewed journals, between July 2010 and June 2011, with comments from the associate editors and editors bringing their expert insight to the reader. The improvement in quality of life and life expectancy of people with diabetes increasingly depends on the success of innovative people in academia and industry to develop new technologies. This accomplishment is in turn crucially related to the interaction between different disciplines of research collaborating in the endeavour to solve the challenges diabetes presents to patients, caregivers, researchers and the industry. Professional interactive relationships between academia and industry will facilitate progress in the field and will lead not only to great innovations but also to their availability for routine clinical care. We hope that the ATTD meeting and the present ATTD Yearbook will help to raise the attention and facilitate the communication of all interested parties in the field of diabetes for the ultimate benefit of our patients. MP’s institution received research grant or support from: Dexcom, Roche, Insulet, Novo Nordisk, Sanofi-Aventis, Eli-Lilly, Andromeda, Medtronic. MP holds stock in CGM3 Ltd and D-Medical and is a consultant to D-Medical, Bristol-Myers-Squibb, AstraZeneca, Physical Logic, Andromeda, Novo Nordisk, Sanofi-Aventis. TB’s institution received research grant support, with receipt of travel and accomodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense and Diamyd. TB received honoria for participating on the speaker’s bureau of Eli Lilly, Novo Nordisk, Bayer and Medtronic; and consulting fees as a member of scientific advisory boards from Bayer, Life Scan, Eli Lilly, Sanofi-Aventis and Medtronic.